within Pharmacolibrary.Drugs.ATC.A;

model A16AB11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.26999999999999996,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.005059999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Taliglucerase alfa is a recombinant enzyme replacement therapy used for the treatment of Gaucher disease type 1. It is a form of the human enzyme beta-glucocerebrosidase produced in carrot cells, and is approved for clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult and pediatric patients with Gaucher disease type 1 following intravenous infusion.</p><h4>References</h4><ol><li><p>Abbas, R, et al., &amp; Alon, S (2015). Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease. <i>PloS one</i> 10(6) e0128986â€“None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0128986&quot;>10.1371/journal.pone.0128986</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26053270/&quot;>https://pubmed.ncbi.nlm.nih.gov/26053270</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AB11;
